Jefferies analyst issued a revised price target for 4D Molecular Therapeutics (NASDAQ:FDMT) stock, lowering it to $40 from the previous $51, while maintaining a Buy rating. Currently trading at $5.48, ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Occasionally, treatments come along that are of greater interest to patients than to doctors.Drops for treating presbyopia ...

D Molecular (FDMT) presented 52-week wet age-related macular degeneration Phase IIb results at this weekend’s Angiogenesis, Exudation, and ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

The DVLA must be notified of eye conditions that affect you, with failure to disclose the condition risking a £1,000 fine ...